Investing
AbbVie trims full-year profit forecast due to higher R&D expenses
© Reuters. Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – AbbVie Inc (NYSE:) cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday.
The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it previously expected.
Read the full article here
-
Investing3 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Investing6 days ago
Are You Missing These Hidden Warning Signs When Hiring?
-
Passive Income3 days ago
How to Create a Routine That Balances Rest and Business Success
-
Make Money6 days ago
7 Common Things You Should Never Buy New
-
Side Hustles4 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles5 days ago
MIT Gives Free Tuition For Families Earning $200,000 or Less
-
Passive Income4 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Investing6 days ago
Google faces call from DuckDuckGo for new EU probes into tech rule compliance By Reuters